FOLFIRINOX as a first line therapy in locally advanced pancreatic cancer and borderline resectable pancreatic cancer: a Meta-analysis

VernacularTitle:5-氟尿嘧啶、亚叶酸钙、伊立替康和奥沙利铂作为一线方案治疗潜在可切除和局部晚期胰腺癌荟萃分析
Author: Xifeng XU ¹ ; Song ZHENG ; Zhen WANG ; Yuan QIAN ; Changku JIA
Author Information

1. 310006,南京医科大学附属杭州医院杭州市第一人民医院杭州市肿瘤医院肿瘤内科
Keywords: Pancreatic cancer; FOLFIRINOX; Resection; Chemotherapy
From: Chinese Journal of Hepatobiliary Surgery 2018;24(1):38-42
CountryChina
Language:Chinese
Abstract: Objective To evaluate the efficacyof the first line chemotherapy FOLFIRINOX (5-Fu,Leucovorin calcium,Irinotecan,Oxaliplatin) as the treatment of pancreatic cancer.Methods Pertinent studies were identified from the PubMed,Cochrane Library and EMBASE.The outcomes were resection rate and radical (R0) resection rate were analyzed.Data were expressed as weighted pooled proportions with 95％ confidence intervals (95％ CI).Results There were thirteen studies with 408 patients with LAPC and BRPC included.After the treatment,42.0％ (95％ CI:28.0％～56.0％) tumorswere resected and 41.0％ (95％ CI:37.0％～45.0％) were underwentR0 resection,and median overall survival ranged from 15.5 to 34.5 months,median progression-free survival ranged from 10.0 to 17.8 months.Conclusion The meta-analysis shows that down-staging after first line FOLFIRINOX-based therapy is noticeable in patients with borderline resectable/unresectable PC,and the adverse events were in control.